Type I interferons and chronic inflammatory demyelinating polyneuropathy: Treatment or cause?

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Muscle and Nerve

• Publication date

  2000-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/(SICI)1097-4598(200003)23:3<307::AID-MUS1>3.0.CO;2-UPMID 10679706
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Placebo-controlled multicentre randomised trial of interferon (cid:1) -1b in treatment of secondary progressive multiple sclerosis

  2005cited by this paper
• Chronic inflammatory demyelinating polyneuropathy after treatment with interferon‐α

  2000cited by this paper
• Clinical improvement following interferon-alpha alone as an initial treatment in CIDP.

  2000cited by this paper
• Clinical improvement following interferon‐α alone as an initial treatment in CIDP

  2000cited by this paper
• Randomized trial of interferon β-1a in chronic inflammatory demyelinating polyradiculoneuropathy

  1999cited by this paper
• Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group.

  1999cited by this paper
• Autoimmune events during interferon beta-1b treatment for multiple sclerosis.

  1999cited by this paper
• Chronic inflammatory demyelinating polyneuropathy during treatment with interferon-α

  1998cited by this paper
• Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

  1998cited by this paper
• Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-alpha 2a.

  1998cited by this paper
• Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

  1998cited by this paper
• Organ-specific autoimmunity and genetic predisposition in interferon-treated HCV-related chronic hepatitis patients.

  1998cited by this paper
• Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-α 2a

  1998cited by this paper
• Hepatitis C-associated autoimmune disorders.

  1998cited by this paper
• Improvement following interferon-alpha 2A in chronic inflammatory demyelinating polyneuropathy

  1997cited by this paper
• A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

  1996cited by this paper
• Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.

  1995cited by this paper
• Immune-mediated side-effects of cytokines in humans.

  1995cited by this paper
• Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy

  1995cited by this paper
• Interferon-alpha may benefit steroid unresponsive chronic inflammatory demyelinating polyneuropathy.

  1995cited by this paper
• Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

  1993cited by this paper
• Development of thyroid autoimmunity after administration of recombinant human interferon-alpha 2b for chronic viral hepatitis.

  1993cited by this paper
• Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria.

  1989cited by this paper
• Acquired Demyelinating Polyneuropathies

  1987cited by this paper

• Novel immunotherapeutic strategies in chronic inflammatory demyelinating polyneuropathy.

  2016cites this paper
• Current immune therapies of autoimmune disease of the nervous system with special emphasis to multiple sclerosis.

  2012cites this paper
• Drug-induced dysimmune demyelinating neuropathies.

  2011cites this paper
• CD4-Positive T Lymphocytes Provide a Neuroimmunological Link in the Control of Adult Hippocampal Neurogenesis1

  2009cites this paper
• Adult Hippocampal Neurogenesis Neuroimmunological Link in the Control of CD 4-Positive T Lymphocytes Provide a Blankenstein

  2009cites this paper
• Recombinant interferon-beta therapy and neuromuscular disorders.

  2009cites this paper
• Chronic neuropathies - chronic inflammatory demyelinating neuropathy and its variants.

  2009cites this paper
• Chronic inflammatory demyelinating polyneuropathy.

  2007cites this paper
• Chronic Inflammatory Demyelinating Polyneuropathy Developed during Interferon-beta Therapy in a Patient with Multiple Sclerosis

  2006cites this paper
• Chronic inflammatory demyelinating polyneuropathy.

  2005cites this paper
• Exacerbation of chronic inflammatory demyelinating polyradiculoneuropathy during interferonbeta-1b therapy in a patient with childhood-onset multiple sclerosis.

  2005cites this paper
• Chronisch inflammatorische demyelinisierende Polyneuropathie - elektrophysiologische Diagnostik

  2003cites this paper
• Contrasting effects of IFNβ and IVIG in children with central and peripheral demyelination

  2003cites this paper
• Severe exacerbation of hepatitis C–associated vasculitic neuropathy following treatment with interferon alpha: A case report and literature review

  2002cites this paper
• Long-term efficacy of Interferon-alpha in chronic inflammatory demyelinating polyneuropathy

  2002cites this paper
• Neuromuscular disease: muscle

  2000cites this paper